Which drug is best for pulmonary hypertensive crisis? new trial aims to find out

NCT ID NCT07667829

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial will compare three drugs—dopamine, norepinephrine, and epinephrine—to see which works best for people experiencing a pulmonary hypertensive crisis, a life-threatening spike in blood pressure in the lungs. The study will enroll 75 adults with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension who are hospitalized. The main goal is to see which drug reduces the risk of death within 28 days, while also monitoring side effects like irregular heartbeats.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

dopamine, norepinephrine, and epinephrine

What this could lead to

If this trial succeeds, it could identify the safest and most effective vasopressor for managing pulmonary hypertensive crisis, potentially improving survival and reducing complications.

What could go wrong

This is a small, early-stage trial (75 participants) comparing existing drugs, so results may not be definitive. The study is not yet recruiting, and outcomes may not apply to all patients with pulmonary hypertension.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION, PULMONARY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder chronic thromboembolic pulmonary hypertension heart failure pulmonary arterial hypertension pulmonary hypertension vascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chinese Academy of Medical Sciences, Fuwai Hospital

    Beijing, Beijing Municipality, 10037, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, 510180, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Zhongnan Hospital of Wuhan University

    Wuhan, Wuhan, 430072, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••